BRAF V600E mutations, present in 3%–7% of iCCA cases, are effectively targeted by the combination of dabrafenib (a BRAF inhibitor) and trametinib (a MEK inhibitor). The gene discussed is BRAF; the disease is infantile convulsions and choreoathetosis.